288 related articles for article (PubMed ID: 11914887)
1. Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.
Soerdjbalie-Maikoe V; Pelger RC; Lycklama à Nijeholt GA; Arndt JW; Zwinderman AH; Papapoulos SE; Hamdy NA
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):494-8. PubMed ID: 11914887
[TBL] [Abstract][Full Text] [Related]
2. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
Brundage MD; Crook JM; Lukka H
Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
[TBL] [Abstract][Full Text] [Related]
3. The treatment of osseous metastases of hormone-refractory prostate cancer with external beam radiotherapy and Strontium-89.
De Ruysscher D; Spaas P; Specenier P
Acta Urol Belg; 1996 Sep; 64(3):13-9. PubMed ID: 8946776
[TBL] [Abstract][Full Text] [Related]
4. Management of the spectrum of hormone refractory prostate cancer.
Clarke NW
Eur Urol; 2006 Sep; 50(3):428-38; discussion 438-9. PubMed ID: 16797118
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
Papatheofanis FJ
J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy of metastatic spinal cord compression in very elderly patients.
Rades D; Hoskin PJ; Karstens JH; Rudat V; Veninga T; Stalpers LJ; Schild SE; Dunst J
Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):256-63. PubMed ID: 17189074
[TBL] [Abstract][Full Text] [Related]
7. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
[TBL] [Abstract][Full Text] [Related]
8. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
Saad F
Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691
[TBL] [Abstract][Full Text] [Related]
9. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial.
Sciuto R; Festa A; Rea S; Pasqualoni R; Bergomi S; Petrilli G; Maini CL
J Nucl Med; 2002 Jan; 43(1):79-86. PubMed ID: 11801708
[TBL] [Abstract][Full Text] [Related]
10. Palliative radiotherapy in prostate cancer.
Catton CN; Gospodarowicz MK
Semin Urol Oncol; 1997 Feb; 15(1):65-72. PubMed ID: 9050141
[TBL] [Abstract][Full Text] [Related]
11. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
Storto G; Klain M; Paone G; Liuzzi R; Molino L; Marinelli A; Soricelli A; Pace L; Salvatore M
Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
[TBL] [Abstract][Full Text] [Related]
12. Spinal cord compression in patients with oral squamous cell carcinoma.
Lee KH; Halfpenny W; Thiruchelvam JK
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Apr; 103(4):e16-8. PubMed ID: 17275365
[TBL] [Abstract][Full Text] [Related]
13. Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and/or external radiotherapy.
Malmberg I; Persson U; Ask A; Tennvall J; Abrahamsson PA
Urology; 1997 Nov; 50(5):747-53. PubMed ID: 9372886
[TBL] [Abstract][Full Text] [Related]
14. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
Higano CS
Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
[TBL] [Abstract][Full Text] [Related]
15. [Metastatic spinal cord compression syndrome. A retrospective analysis of 297 patients].
Schmidt LA; Pfeiffer P
Ugeskr Laeger; 2006 Aug; 168(34):2810-3. PubMed ID: 16942703
[TBL] [Abstract][Full Text] [Related]
16. Treatment and prognosis of patients with paraplegia or quadriplegia because of metastatic spinal cord compression in prostate cancer.
Nagata M; Ueda T; Komiya A; Suzuki H; Akakura K; Ishihara M; Tobe T; Ichikawa T; Igarashi T; Ito H
Prostate Cancer Prostatic Dis; 2003; 6(2):169-73. PubMed ID: 12806378
[TBL] [Abstract][Full Text] [Related]
17. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
Heidenreich A; Hofmann R; Engelmann UH
J Urol; 2001 Jan; 165(1):136-40. PubMed ID: 11125382
[TBL] [Abstract][Full Text] [Related]
18. Relative efficacy of 32P and 89Sr in palliation in skeletal metastases.
Nair N
J Nucl Med; 1999 Feb; 40(2):256-61. PubMed ID: 10025832
[TBL] [Abstract][Full Text] [Related]
19. Preliminary results of spinal cord compression recurrence evaluation (score-1) study comparing short-course versus long-course radiotherapy for local control of malignant epidural spinal cord compression.
Rades D; Lange M; Veninga T; Rudat V; Bajrovic A; Stalpers LJ; Dunst J; Schild SE
Int J Radiat Oncol Biol Phys; 2009 Jan; 73(1):228-34. PubMed ID: 18539406
[TBL] [Abstract][Full Text] [Related]
20. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
Papatheofanis FJ
J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
